Related Experiment Video
Updated: Jun 25, 2026

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Therapeutic management of patent ductus arteriosus
Arpitha Chiruvolu1, Mambarath A Jaleel
1Department of Pediatrics, Division of Neonatology, Baylor University Medical Center, Dallas, Texas 75246, USA. Arpitha.Chiruvolu@baylorhealth.edu
Abstract:
Management of patent ductus arteriosus (PDA) in premature neonates has always been a challenge to the neonatologist and continues to be a controversial topic. Indications for treatment are not clear. Approximately 40% of ductus arteriosus close spontaneously even in extremely-low-birth-weight neonates. Prophylactic or early pre-symptomatic treatment may unnecessarily expose these babies, in whom the ductus might close spontaneously, to pharmacologic agents and their adverse effects. On the other hand, with advancing postnatal age, delaying treatment could potentially decrease successful medical closure thereby increasing the rate of surgical ligation and the complications associated with surgery. We tried to develop some clinical guidelines for management of PDA in premature neonates based on evidence, or lack thereof, and experience.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Aortic Regurgitation IV: Nursing Management
Mitral Stenosis IV: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Rheumatic Heart Disease III: Medical Management

